Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MSE Pharmazeutika is a German pharmaceutical company specializing in mitochondrial medicine and the development of high-quality nutritional supplements and therapeutic compounds. Founded by Dr. Franz Enzmann, a pioneer in Coenzyme Q10 research, the company focuses on substances that support cellular energy production and combat oxidative stress. Their product portfolio includes various formulations of ubiquinone (Q10), vitamins, and minerals designed to address mitochondrial deficiencies and metabolic disorders. MSE Pharmazeutika operates primarily in the European market, providing evidence-based solutions for practitioners and patients focused on metabolic health. The company is recognized for its liquid Q10 formulations, which are designed for enhanced bioavailability.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MSE Pharmazeutika.